Close Menu

drug development

NEW YORK (GenomeWeb News) – A consortium comprising six industry players and academic partners has been created to identify kinases that could serve as drug targets.

The draft guidance provides non-binding recommendations on ways to use genomic information in early-phase drug development.

The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.

Early studies involving a monoclonal antibody against PCSK9 show promise in lowering LDL in hypercholesterolemia patients. According to at least one published study, Pfizer is investigating assay methods for monitoring treatment response by gauging PCSK9 levels.

Clinical Data, which at one point was working toward becoming a personalized medicine company, is now "considering the sale of its genetic testing and biomarker development business."

PGx & molecular Dx

The firm also said that it and NextGen Sciences have developed a protein biomarker assay method that can provide rapid, reproducible, quantitative measurement of protein expression in formalin-fixed, paraffin-embedded tissue.

Although the Pharmacogenomics Training and Research Laboratory will primarily focus on training students in the discipline, it could also enable R&D partnerships with industry players.

Snippets: Apr 22, 2009

Premium

Johns Hopkins University's Genetics and Public Policy Center, National Cancer Institute, Santoris, RayBiotech

The new budget and stimulus funds will fuel the Genome Atlas, a personalized medicine platform, and more grants to young investigators.

Pages

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.